Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Repurposing antiserotonergic drugs for the treatment of breast cancer
FY 2013-14
Summary
Breast cancer is the leading cause of cancer death among females worldwide. This may be due to the ability of breast cancer stem cells to resist standard cancer treatments, such as chemotherapy and radiation. Breast cancer stem cells have both the ability to self-renew and the capacity to differentiate into non-tumorigenic cancer cells, which make up the bulk of tumors. If they get left behind after treatment, they can initiate the formation of a new tumor and cause patients to relapse. Consequently, there is a need for new therapies that have the ability to kill breast cancer stem cells. In order to develop these new therapies, it is crucial to identify the signaling pathways that are essential for breast cancer stem cell survival and proliferation. Recent studies have shown that serotonin signaling may be important for the activity of breast cancer stem cells. For example, a number of serotonin receptors are upregulated in human breast cancer tissues relative to normal breast tissue. As a result, targeting different components of the serotonergic system may be a way of targeting breast cancer stem cells. Many antiserotonergic drugs are currently being used to treat depression and other mood-related disorders. The goals of this research project are to asses the ability of approved antiserotonergic drugs to selectively kill breast cancer stem cells and to determine whether or not they could be repurposed for the treatment of breast cancer. The idea of repurposing approved drugs has recently gained momentum in response to the decrease in the productivity of pharmaceutical companies. Not only is this approach faster and less expensive than the traditional method of drug discovery, there are also fewer risks associated with this approach because approved drugs have already passed phase 1 clinical trials and are safe for use in humans. To accomplish this research goal, several approved antiserotonergic drugs will be tested in human breast cancer cell lines derived from patients to determine which drugs have the ability to inhibit the proliferation of breast cancer cells. The drugs that significantly inhibit proliferation will be tested in sphere-forming assays. The sphere-forming assay is used as a functional assay for stem cells. Many breast cancer cell lines can be propagated as spheres by growing them in stem cell media containing human growth factors. In a sphere-forming assay, established spheres are dissociated and single cells are plated in the presence of various concentrations of a drug. After 4 days of incubation, the spheres are counted to determine if the drug inhibits sphere formation in a dose-dependent manner. The drugs that significantly inhibit sphere formation may be targeting breast cancer stem cells. To test this, mice with pre-established tumors will be treated with one of the following: the drug, chemotherapy, the drug plus chemotherapy, or a control substance. The tumors will be monitored for several weeks to determine whether they stop growing or shrink in response to the drug. At the end of study, the tumors will be surgically removed and further studied to determine if the drug caused any molecular changes within the tumor cells or induced any cell death. If the drug by itself or in conjunction with chemotherapy shrinks the tumor significantly more than chemotherapy does by itself, the drug has potential for becoming a new breast cancer therapy or for supplementing standard chemotherapy.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
311711
Name
Bisson Jennifer
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Repurposing antiserotonergic drugs for the treatment of breast cancer
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Breast Tumor-Initiating Cells; Cancer Stem Cell Model; Repurposing Approved Drugs; Serotonin
Abstract
Breast cancer is the leading cause of cancer death among females worldwide. This may be due to the ability of breast cancer stem cells to resist standard cancer treatments, such as chemotherapy and radiation. Breast cancer stem cells have both the ability to self-renew and the capacity to differentiate into non-tumorigenic cancer cells, which make up the bulk of tumors. If they get left behind after treatment, they can initiate the formation of a new tumor and cause patients to relapse. Consequently, there is a need for new therapies that have the ability to kill breast cancer stem cells. In order to develop these new therapies, it is crucial to identify the signaling pathways that are essential for breast cancer stem cell survival and proliferation. Recent studies have shown that serotonin signaling may be important for the activity of breast cancer stem cells. For example, a number of serotonin receptors are upregulated in human breast cancer tissues relative to normal breast tissue. As a result, targeting different components of the serotonergic system may be a way of targeting breast cancer stem cells. Many antiserotonergic drugs are currently being used to treat depression and other mood-related disorders. The goals of this research project are to asses the ability of approved antiserotonergic drugs to selectively kill breast cancer stem cells and to determine whether or not they could be repurposed for the treatment of breast cancer. The idea of repurposing approved drugs has recently gained momentum in response to the decrease in the productivity of pharmaceutical companies. Not only is this approach faster and less expensive than the traditional method of drug discovery, there are also fewer risks associated with this approach because approved drugs have already passed phase 1 clinical trials and are safe for use in humans. To accomplish this research goal, several approved antiserotonergic drugs will be tested in human breast cancer cell lines derived from patients to determine which drugs have the ability to inhibit the proliferation of breast cancer cells. The drugs that significantly inhibit proliferation will be tested in sphere-forming assays. The sphere-forming assay is used as a functional assay for stem cells. Many breast cancer cell lines can be propagated as spheres by growing them in stem cell media containing human growth factors. In a sphere-forming assay, established spheres are dissociated and single cells are plated in the presence of various concentrations of a drug. After 4 days of incubation, the spheres are counted to determine if the drug inhibits sphere formation in a dose-dependent manner. The drugs that significantly inhibit sphere formation may be targeting breast cancer stem cells. To test this, mice with pre-established tumors will be treated with one of the following: the drug, chemotherapy, the drug plus chemotherapy, or a control substance. The tumors will be monitored for several weeks to determine whether they stop growing or shrink in response to the drug. At the end of study, the tumors will be surgically removed and further studied to determine if the drug caused any molecular changes within the tumor cells or induced any cell death. If the drug by itself or in conjunction with chemotherapy shrinks the tumor significantly more than chemotherapy does by itself, the drug has potential for becoming a new breast cancer therapy or for supplementing standard chemotherapy.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bisson, Jennifer
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~